Literature DB >> 18559875

Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

Mitchell Machtay1, Jennifer Moughan, Andrew Trotti, Adam S Garden, Randal S Weber, Jay S Cooper, Arlene Forastiere, K Kian Ang.   

Abstract

PURPOSE: Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT.
METHODS: Patients were analyzed from a subset of three previously reported Radiation Therapy Oncology Group (RTOG) trials of CCRT for locally advanced SCCHN (RTOG 91-11, 97-03, and 99-14). Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube >or= 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years. Case-control analysis was performed, with a multivariable logistic regression model that included pretreatment and treatment potential factors.
RESULTS: A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity. On multivariable analysis, significant variables correlated with the development of severe late toxicity were older age (odds ratio 1.05 per year; P = .001); advanced T stage (odds ratio, 3.07; P = .0036); larynx/hypopharynx primary site (odds ratio, 4.17; P = .0041); and neck dissection after CRT (odds ratio, 2.39; P = .018).
CONCLUSION: Severe late toxicity after CCRT is common. Older age, advanced T-stage, and larynx/hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was associated with an increased risk of these complications.

Entities:  

Mesh:

Year:  2008        PMID: 18559875      PMCID: PMC4911537          DOI: 10.1200/JCO.2007.14.8841

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  30 in total

1.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Authors:  G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

2.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

3.  Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice.

Authors:  G Stüben; O Thews; C Pöttgen; K Knühmann; P Vaupel; M Stuschke
Journal:  J Cancer Res Clin Oncol       Date:  2001       Impact factor: 4.553

4.  Swallowing function after chemoradiation for advanced stage oropharyngeal cancer.

Authors:  Samuel G Shiley; Christopher A Hargunani; Judith M Skoner; John M Holland; Mark K Wax
Journal:  Otolaryngol Head Neck Surg       Date:  2006-03       Impact factor: 3.497

Review 5.  Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization.

Authors:  Joel S Greenberger; Michael W Epperly
Journal:  In Vivo       Date:  2007 Mar-Apr       Impact factor: 2.155

6.  Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

Authors:  A S Garden; J Harris; E E Vokes; A A Forastiere; J A Ridge; C Jones; E M Horwitz; B S Glisson; L Nabell; J S Cooper; W Demas; E Gore
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

Review 7.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

8.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

9.  Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life.

Authors:  Ken Dornfeld; Joel R Simmons; Lucy Karnell; Michael Karnell; Gerry Funk; Min Yao; Judith Wacha; Bridget Zimmerman; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-06       Impact factor: 7.038

10.  Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.

Authors:  Patrizia Olmi; Sergio Crispino; Carlo Fallai; Valter Torri; Francesca Rossi; Andrea Bolner; Maurizio Amichetti; Marco Signor; Raffaella Taino; Massimo Squadrelli; Alessandro Colombo; Alessandro Ardizzoia; Pietro Ponticelli; Giovanni Franchin; Emilio Minatel; Carlo Gobitti; Guido Atzeni; Alessandro Gava; Monica Flann; Silvia Marsoni
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-01-01       Impact factor: 7.038

View more
  346 in total

1.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

Authors:  Phuc Felix Nguyen-Tan; Qiang Zhang; K Kian Ang; Randal S Weber; David I Rosenthal; Denis Soulieres; Harold Kim; Craig Silverman; Adam Raben; Thomas J Galloway; André Fortin; Elizabeth Gore; William H Westra; Christine H Chung; Richard C Jordan; Maura L Gillison; Marcie List; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

3.  [Multimodal laryngeal preservation: current data-based opinion].

Authors:  A Dietz; A Boehm; G Wichmann; D Niederwieser; S Dietzsch; M Fuchs
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

4.  The emergence of endoscopic head and neck surgery.

Authors:  Floyd Christopher Holsinger; Alexander D Sweeney; Kitti Jantharapattana; Ahmed Salem; Randal S Weber; Woong Youn Chung; Carol M Lewis; David G Grant
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

5.  Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer.

Authors:  Peter A Paximadis; Michael E Christensen; Greg Dyson; Dev P Kamdar; Ammar Sukari; Ho-Sheng Lin; George H Yoo; Harold E Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

6.  (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.

Authors:  Thomas Bird; Sally Barrington; Selvam Thavaraj; Jean-Pierre Jeannon; Andrew Lyons; Richard Oakley; Ricard Simo; Mary Lei; Teresa Guerrero Urbano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-28       Impact factor: 9.236

7.  Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy.

Authors:  Candan Demiroz; Jeffrey M Vainshtein; Georgios V Koukourakis; Orit Gutfeld; Mark E Prince; Carol R Bradford; Gregory T Wolf; Scott McLean; Francis P Worden; Douglas B Chepeha; Matthew J Schipper; Jonathan B McHugh
Journal:  Head Neck       Date:  2013-11-18       Impact factor: 3.147

Review 8.  Radiation-induced fibrosis: mechanisms and implications for therapy.

Authors:  Jeffrey M Straub; Jacob New; Chase D Hamilton; Chris Lominska; Yelizaveta Shnayder; Sufi M Thomas
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-25       Impact factor: 4.553

9.  Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Authors:  Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

Review 10.  Treatment de-intensification strategies for head and neck cancer.

Authors:  Jacqueline R Kelly; Zain A Husain; Barbara Burtness
Journal:  Eur J Cancer       Date:  2016-10-15       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.